Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
[EN] When your studies meet Good Laboratory Practices!
Home . Resources . [EN] When your studies meet Good Laboratory Practices!
Since 2018, the site of Oncodesign, located in the South of Paris, has been certified Good Laboratory Practices (GLP) by the French regulatory authorities (ANSM).
Our scientists develop, validate and perform your regulatory bioanalysis studies, in a quality environment and in accordance with Good Laboratory Practices. Our quality management system, under the responsibility of the BU Service Quality Assurance Manager, ensures the highest level of regulatory compliance along with the reliability and integrity of your experimental data. We carefully follow the guidelines for industry in a spirit of continuous quality improvement.
Our commitment, in line with our values, is to provide high quality services.